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ABSTRACT 
 
Humans receive countless sensory inputs from the outside world to which they 
assign a certain level of emotional significance. However, there are times when an 
individual may assign an abnormally high level of emotional salience to an otherwise 
non-significant event, resulting in an inappropriate allocation of attention as seen in the 
hallucinations and psychosis associated with schizophrenia. Several brain regions are 
involved in this emotional processing, including the medial prefrontal cortex (mPFC) and 
the ventral tegmental area (VTA). We have previously shown that activation of mPFC 
cannabinoid (CB1) receptors in rats causes a potentiated fear response to a normally non-
salient sensory event (Laviolette & Grace, 2006a). To further investigate the cause of this 
increased fear response we performed in vivo extracellular electrophysiology recordings 
along with olfactory fear conditioning in awake, behaving animals. We observed a 
biphasic effect across both methodologies where an intra-mPFC low dose CB1 agonist 
caused an increase in spontaneous neural activity in VTA DA cells and a potentiated fear 
response, while an intra-mPFC high dose CB1 agonist caused a decrease in spontaneous 
neural activity in VTA DA cells and a block of normal fear memory acquisition, an effect 
that was rescued using an intra-VTA GABA-B receptor antagonist. Given the 
implications of the dopamine and cannabinoid systems in schizophrenia, these studies 
could provide important insights into the underlying neural activity of the emotional 
processing deficits associated with the disorder. 
 
 
Keywords: Prefrontal Cortex, Ventral Tegmental Area, Cannabinoids, Dopamine, 
Electrophysiology, Fear Conditioning, GABA, Emotion Processing  
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1. Introduction 
Under normal circumstances, people receive countless sensory inputs from the 
outside world to which they assign appropriate emotional significance. Through this 
mechanism, we are able to react accordingly based on the emotional importance or non-
importance of an event. However, there are times when this emotional processing 
mechanism does not work as it should, as in schizophrenia or post-traumatic stress 
disorder (PTSD). An individual may assign an abnormally high level of emotional 
salience to an otherwise non-significant event resulting in an inappropriate allocation of 
attention and, in extreme cases, hallucinations and psychosis. Thus far, a considerable 
body of research has identified several brain regions involved in this emotional 
processing circuit, including the medial prefrontal cortex (mPFC) and the ventral 
tegmental area (VTA). These areas comprise components of the mesocorticolimbic 
circuit, and contain high levels of dopamine (DA) and cannabinoid CB1 receptors, which 
both play a critical role in modulating emotionally salient stimuli.  Anatomically, the 
mPFC and VTA communicate via ascending and descending functional projections and 
can bi-directionally modulate neuronal activity dynamics across the pathway.  
Additionally, the DA and CB1 systems have been shown to functionally interact with 
each other and are implicated in the etiology and treatment of schizophrenia. In this 
thesis, I will investigate the interaction between these neurotransmitter systems within the 
mesocorticolimbic circuit, a neural system critical for emotional processing. Specifically, 
my research focuses on how cortical cannabinoid transmission can alter sub-cortical 
neuronal activity patterns in the VTA and thereby modulate the salience of incoming 
sensory information and associative memory formation. In addition, I will investigate the 
2 
 
 
specific pharmacological mechanisms controlling functional interactions between the 
PFC and VTA, in the context of emotional processing, at the neuronal and behavioural 
levels of analysis.  
 
1.1 Emotional processing and the mesocorticolimbic system 
 
1.1a The ventral tegmental area 
The mesocorticolimbic system is often known as the “reward” circuit in the brain 
as it’s the system that mediates the rewarding properties of various commonly abused 
drugs like cocaine, morphine, nicotine and amphetamine (Wise, 2004). However, this 
circuit also plays an important role in emotional processing in a more general sense, 
including the processing of other emotionally salient experiences, such as aversive 
stimuli. Situated deep within the midbrain is the VTA. The VTA contains a large number 
of DA cell bodies, classified as the “A10” neurons, that project to different structures 
within the mesocorticolimbic circuit, including the amygdala, the nucleus accumbens 
(NAc) and the prefrontal cortex (PFC). This dopamine signal has been shown to play a 
number of different functional roles including the processing and integration of 
emotionally salient information (Laviolette & Grace, 2006b), which will be discussed 
later in more detail. While each area of the mesocorticolimbic circuit plays an important 
role, the functional and anatomical connections between the VTA and the mPFC have 
been extensively studied and are the main focus of pharmacological manipulation in this 
thesis.  
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 The direct and reciprocal neural projections from the VTA to the mPFC have 
been characterized previously. Using a triple-labelling procedure that combined 
anterograde and retrograde tracing with immunocytochemical identification, Sesack and 
Carr (2002) were able to show that glutamatergic projections from the mPFC innervated 
only the DA cells in the VTA that project back up to mPFC, and not DA cells that project 
to different parts of the circuit such as the NAc. This suggests evidence of a closed-circuit 
feedback loop, where the activity of mesocortical DA cells directly influence cortical 
activity in mPFC and vice versa. Indeed, Peters, Lewis and O’Donnell (2000) 
demonstrated the synchronous activity between the VTA and mPFC using intra- and 
extracellular recordings and showed that DA activity in the VTA was able to control 
membrane potential states of pyramidal cells in mPFC. But the effect is not just limited to 
pyramidal cells – Tseng et al. (2006) were able to show that VTA stimulation directly 
altered the firing frequency of fast-spiking interneurons located in the mPFC. Conversely, 
stimulation of neurons in the PFC have been shown to have both excitatory and inhibitory 
effects on DA cells in the VTA (Gao et al., 2007). Thus, the anatomical connections 
between these two areas are well-known but what does this mean on a functional level? 
The functions of the mesolimbic pathway are numerous but have been shown to be 
important in the processing of emotionally salient information. Acting mainly through a 
DA-dependent mechanism, the VTA-PFC pathway can encode signals of both salience 
and valence, which will be discussed in more detail below (see 1.1c).    
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1.1b The prefrontal cortex 
The PFC plays a crucial role in mediating various behaviours, allocating attention, 
working memory, decision-making and regulating subcortical brain structures, among 
other things. As discussed previously, it receives projections from the VTA along with 
most other brain structures including those in the mesocorticolimbic circuit such as the 
NAc and basolateral amygdala (BLA). It also sends afferent fibres to many of those areas 
in return, providing a modulatory “top-down” effect on a wide range of neural activity. 
The PFC is a relatively large region and can be subdivided into different structural areas 
with unique, yet overlapping, functions. The mPFC includes both the infralimbic (IL) and 
prelimbic (PL) cortices and has been implicated in the processing of associative 
memories, including the acquisition, maintenance and extinction phases (Miller, 2000). In 
fact, research has shown the ability of the mPFC to encode emotional conditioned 
associations exists at both the behavioural and the single neuron level. Using an olfactory 
fear conditioning procedure, Laviolette, Lipski and Grace (2005) demonstrated that 
individual neurons in the mPFC were able to show a learned association to an 
emotionally salient associative fear stimulus. In contrast, neurons in the more ventral IL, 
show increased associative activity during the extinction (unlearning) of previously 
acquired associative fear memories (Milad & Quirk, 2002). Furthermore, Milad, Vidal-
Gonzalez and Quirk (2004) were able to show this effect at a behavioural level as well, 
reporting that stimulation of the IL could modulate the expression of a conditioned fear 
response. These reports are consistent with various other studies implicating the mPFC as 
an important brain region for emotional memory processing (Feenstra, Vogel, 
Botterblom, Joosten, & Bruin, 2001; LeDoux, 1995; Miller, 2000; Williams et al., 2004).  
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The functional role of the mPFC in emotional processing becomes increasingly 
evident when examining disorders that are characterized by structural and functional 
mPFC deficits, such as schizophrenia (Laviolette & Grace, 2006b). Schizophrenia is a 
complex, multifaceted neuropsychiatric disorder exhibiting a plethora of symptom 
profiles. However, there are various aspects of the disease that have been repeatedly 
observed, one of which includes prefrontal abnormalities. Brain volume reduction has 
been shown, as well as reduced connectivity from the PFC to other brain regions 
(Keshavan, Tandon, Boutros, & Nasrallah, 2008). Also, tasks known to involve frontal 
lobe function are often performed poorly by patients with schizophrenia (Berman et al., 
1997; Keshavan et al., 2008). Williams et al. (2004) conducted an imaging study to 
examine how schizophrenia patients processed images of fearful stimuli versus controls. 
They examined brain activity as well as skin conductance and found that paranoid 
schizophrenic patients displayed heightened autonomic response but reduced neural 
activity in the prefrontal-amygdala circuit. This not only shows reduced activity in the 
PFC but also an interesting disconnect between the autonomic response to an emotional 
cue and the corresponding neural activity.   
 
1.1c Dopamine and emotional processing 
As discussed previously, both the VTA and mPFC have been implicated for their 
role in the processing of emotionally salient stimuli. Much of their involvement can be 
attributed to the activity of DA throughout the mesocorticolimbic system, where a large 
number of DA receptors are concentrated. Thus far, two main families of DA receptors 
have been classified. They are divided into D1-like and D2-like subtypes, and have 
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differing synaptic locations and intracellular signalling effects. The D1-like subtype 
consists of the D1 and D5 receptor types, which are mainly found post-synaptically and 
whose activation generally stimulates adenylyl cyclase. In contrast, the D2-like subtype 
consists of the D2, D3 and D4 receptors which can be located both pre- and post-
synaptically and whose activation generally inhibits adenylyl cyclase (Missale, Nash, 
Robinson, Jaber, & Caron, 1998; Vallone, Picetti, & Borrelli, 2000).  
 A large cluster of DA cell bodies resides in the VTA and it is from here that they 
have their well-known effect on drug addiction and reward. Through projections to the 
BLA, NAc and PFC, DA activity has also been shown to play an important role in how 
the brain processes the salience of specific sensory stimuli (Adinoff, 2004; Berridge & 
Robinson, 1998). For example, Nader & LeDoux (1999) found that systemic application 
of quinpirole activated DA autoreceptors, leading to a decrease in DA transmission that 
correlated with a decrease in fear behaviour by blocking the retrieval of a learned CS-US 
association. In a similar vein, neuroleptic medications that act through antagonizing DA 
receptors (specifically clozapine and haloperidol) were found to block the acquisition of a 
conditioned fear association (Inoue, Tsuchiya & Koyama, 1996). Conversely, there are a 
number of studies showing the opposite effect – an increase in DA activity in the 
mesocorticolimbic circuit can lead to potentiated fear responses and heightened 
conditioned fear associations (Killcross, Everitt, & Robins, 1997; Morrow, Elsworth, & 
Roth, 1996; Miczek & Luttinger, 1978; Borowski & Kokkinidis, 1998).  
 Detailed work has been conducted looking at the role of DA in the mPFC 
specifically, and how dopaminergic transmission in this brain region can affect emotional 
processing. Shah, Sjovold and Treit (2004) examined the anxiolytic effects of blocking 
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DA receptors in the mPFC during elevated plus maze and shock-probe burying tests. 
They found that antagonizing mPFC D4 receptors led to a decrease in fear-related 
behaviour in both tests, demonstrating an important role for the D4 receptor in processing 
emotionally salient information. Similar results have been found using an olfactory fear 
conditioning paradigm, where systemic administration of a D4 antagonist was able to 
block the ability of single mPFC neurons to learn an olfactory fear association. This 
effect was replicated at the behavioural level, where mPFC infusions of the same D4 
antagonist were able to block the expression of a normal fear response to a footshock-
paired odor (Laviolette et al., 2005). Further investigation revealed a bi-directional role 
for D4 receptors during behavioural fear conditioning, where activation of mPFC D4 
receptors was able to potentiate a fear response to a normally non-salient subthreshold 
footshock while also blocking a normal fear response to a suprathreshold footshock 
(Lauzon, Bishop, & Laviolette, 2009). Yet DA modulation of emotional processing is not 
limited to the D4 receptor subtype. For example, the D1 subtype has also been shown as a 
crucial mediator in the processing of emotionally salient stimuli. Activating D1 receptors 
in mPFC can block the expression of a suprathreshold associative fear memory that has 
been learned previously (Lauzon et al., 2009) and can also block the expression of a 
previously learned morphine reward memory, an effect that can be rescued by co-
administration of a cAMP signaling inhibitor (Lauzon, Bechard, Ahmad, & Laviolette, 
2013).    
 DA dysfunction is associated with a number of different disorders ranging from 
Parkinson’s disease to Tourette’s syndrome to schizophrenia (Missale et al., 1998). The 
role of DA dysfunction in schizophrenia will be discussed in further detail below and 
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while its importance is evident, DA is not the sole neurotransmitter involved in emotional 
processing. Another system, the cannabinoid system, is also crucial for signalling the 
importance of emotional stimuli. 
 
1.2 The cannabinoid system  
 
1.2a Actions in the central nervous system 
Two main cannabinoid receptors, CB1 and CB2, have been characterized thus far. 
As CB2 has been found predominantly in the periphery, we focused our attention 
specifically on the CB1receptor. Within the central nervous system (CNS) the CB1 
receptor is prominent and can be found in areas associated with emotional processing 
such as the amygdala, striatum, hippocampus, and frontal cortex (Dove Pettit, Harrison, 
Olson, Spencer & Cabral, 1998; Moldrich & Wenger, 2000). CB1 is an inhibitory G-
protein coupled receptor and is located presynaptically, where it inhibits the release of 
neurotransmitters by a number of different signalling events including the closing of 
Ca2+ channels, opening of K+ channels, and the inhibition of adenylyl cyclase activity 
(Hirvonen et al., 2012; Lupica, Riegel, & Hoffman, 2004; Piomelli, 2003). CB1 receptors 
have been found in areas of both the mPFC and the VTA (Moldrich & Wenger, 2000; 
Tsou, Brown, Sañudo-Peña, Mackie, & Walker, 1998; Zangen, Solinas, Ikemoto, 
Goldberg, & Wise, 2006) which, as discussed previously, provide important modulation 
for the processing of emotionally salient information.  
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1.2b Cannabinoids and emotional processing 
Several lines of evidence exist showing the importance of CB1 receptor activity in 
emotion-related behaviours and the processing of emotionally relevant stimuli. In human 
self-report studies, cannabinoid consumption was shown to cause mood-related 
disturbances and influence sensory perception in participants, along with altering the 
significance of incoming sensory information (Green, Kavanagh, & Young, 2003; 
Wachtel, ElSohly, Ross, Ambre, & de Wit, 2002). In animal studies, Marsicano et al. 
(2002) report that CB1 knockout mice are unable to extinguish an aversive conditioned 
fear memory of an auditory cue paired with a footshock. CB1 knockout mice have also 
been shown to display abnormal emotional responses to behavioural paradigms like the 
resident-intruder test and a chronic unpredictable mild stress paradigm (Martin, Ledent, 
Parmentier, Maldonado, & Valverde, 2002). Behaviours such as increased aggression and 
heightened depressive responses were commonly observed, implying that the CB1 
receptor is essential for normal emotional behaviours. Pharmacological modulation of 
CB1 receptors has also been shown to affect the salience of incoming sensory 
information. Laviolette and Grace (2006a) performed olfactory fear conditioning 
experiments and demonstrated an increased fear response to a normally non-fearful 
stimulus in rats during mPFC CB1 activation, an effect that was completely blocked 
using a CB1 antagonist. Furthermore, CB1 receptor transmission along the BLA-mPFC 
pathway appears to be crucial for the encoding of emotional memories, with both 
systemic and local infusions of the CB1 antagonist AM-251 blocking the acquisition of a 
conditioned fear association (Tan, Lauzon, Bishop, Bechard, & Laviolette, 2010). 
Subsequent electrophysiological experiments showed a dual role for CB1 receptor 
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transmission within the BLA, with neurons of the mPFC showing an increase in neural 
firing frequency and bursting during BLA CB1 activation and a decrease in activity 
during BLA CB1 blockade (Tan et al., 2011). Thus it appears that cannabinoid 
transmission within the BLA is able to modulate the processing of an emotional fear 
association via neuronal inputs to areas of the mPFC.         
 
1.2c Interactions with the dopamine system 
There are several functional and anatomical interactions between the cannabinoid 
and DA systems in the CNS. CB1 receptors can be found in brain regions innervated by 
DA inputs as well as regions that contain high levels of DA receptors (McDonald & 
Mascagni, 2001; Moldrich & Wenger, 2000). In fact, in the prefrontal cortex CB1 and the 
D2-receptor subtype are co-localized at terminals of presumed GABAergic synapses, 
with activation of either receptor causing a suppression of GABA release onto layer V 
pyramidal cells (Chiu, Puente, Grandes, & Castillo, 2010). Indeed, numerous studies 
support the finding that CB1 modulation can play an important role in DA activity within 
the brain. Systemic administration of the CB1 agonist delta-9-tetrahydrocannabinol 
(THC) or WIN-55, 212-2 (WIN55) has been shown to increase the firing rate and 
bursting activity of DA neurons in the VTA that project to the PFC (Diana, Melis, & 
Gessa, 1998; French, Dillon, & Wu, 1997). The reverse effect has also been 
demonstrated, with intravenous (i.v.) administration of THC or WIN55 increasing the 
firing rate of PFC pyramidal neurons that project to VTA (Pistis, Porcu, Melis, Diana, & 
Gessa, 2001). A study by Polissidis et al. (2010) revealed that by administering systemic 
doses of either THC or WIN55, the biosynthesis of DA was actually increased in regions 
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like the dorsal striatum, NAc, PFC and amygdala. Furthermore, the amount of 
phosphorylated DARPP-32 (a DA- and cAMP-regulated neuronal phosphoprotein that 
can act as an index of DA neurotransmission) increased in the same regions, indicating a 
key role for cannabinoids in the synthesis and activity of midbrain DA transmission. For 
example, a well-demonstrated mechanism by which endocannabinoids modulate DA 
activity is through a retrograde messenger system (Alger, 2002). Release by the 
depolarized postsynaptic cell enables the diffusion of endocannabinoids such as 2-
arachidonoyl-glycerol (2-AG) “backward” across the synaptic cleft where they can bind 
to the presynaptic cell and cause a suppression of neurotransmitter release. This method 
of endocannabinoid signalling implies a crucial role for the CB1 receptor in shaping 
specific patterns of neuronal firing, especially for VTA DA cells. By stimulating the PFC, 
it was discovered that 2-AG can suppress firing frequency and bursting activity in DA 
cells of the VTA, indicating that DA neurons can release 2-AG on demand to alter their 
own firing pattern (Melis et al., 2004). It is evident that exogenous and endogenous 
cannabinoids can act through both post- and pre-synaptic mechanisms to influence DA 
activity in various regions throughout the brain. The understanding of this interaction 
between CB and DA systems becomes increasingly important when considering the role 
both systems play in specific neuropsychiatric disorders such as schizophrenia.            
       
1.3 Implications for schizophrenia 
Schizophrenia is a complicated, multi-faceted disorder with various neurological 
and behavioural symptoms whose etiology is not yet fully understood. A major facet of 
the disease comes from the inability to accurately process emotionally salient 
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information. Where unaffected individuals can attribute appropriate emotional 
significance to incoming sensory information, patients with schizophrenia have been 
known to assign an inaccurate amount of importance to specific sensory events, whether 
externally or internally generated. This dysfunction of emotional processing can manifest 
itself in the form of “positive” or “negative” symptoms of the disorder. Positive 
symptoms can include sensory hallucinations and psychotic delusions while negative 
symptoms include things like anhedonia, apathy and social withdrawal (Berman et al., 
1997). Much of the focus on treatment has historically revolved around DA receptors, 
which will be discussed presently. 
 
1.3a The DA hypothesis of schizophrenia 
The DA hypothesis of schizophrenia garnered popularity based on the 
observations of pharmacological DA manipulation and the effect it had on the psychotic 
symptoms of the disease. Primarily, D2 receptor antagonists were (and still are) found to 
be the most effective antipsychotic medication to help alleviate the positive symptoms of 
schizophrenia (Kapur & Mamo, 2003). Furthermore, it was discovered that drugs causing 
excessive DA release were able to mimic the psychotic symptoms that many 
schizophrenic patients experience, in non-schizophrenic individuals (Angrist, 
Sathananthan, Wilk, & Gershon, 1974). Thus, it was thought that schizophrenia could be 
characterized as a disease of excessive DA transmission. However, various lines of 
evidence began to emerge that largely discredited this simplified view, such as the fact 
that pathological alterations in DA transmission in schizophrenic patients could rarely be 
confirmed due to the confounds of treatment with antipsychotic medication (Lieberman, 
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Sheitman & Kinon, 1997). Nonetheless, although the etiology of the disease is not based 
entirely on DA transmission, the importance of DA in emotional processing is evident 
and given the correlation between DA, emotional processing, and the deficits seen in 
schizophrenia, it is clear that this neurotransmitter system plays a crucial role in the 
positive symptoms of the disorder.      
 
1.3b Cannabinoids and paranoid schizophrenia 
As stated previously, CB1 receptor activity has been shown to alter the perception 
of incoming sensory information, including emotionally relevant stimuli. Those same 
processing deficits are commonly seen in patients with schizophrenia, specifically the 
paranoid schizophrenic subtype. Characterized by persistent delusions and/or 
hallucinations of persecution and suspiciousness, the symptoms of paranoid 
schizophrenia are similar to the effects experienced by non-schizophrenic individuals 
after excessive cannabis exposure (Green et al., 2003; Wachtel et al., 2002). Furthermore, 
there are several pieces of evidence linking the CB1 system to schizophrenia. A long-
term study by Andreasson, Engstrom, Allebeck and Rydberg (1987) looked at Swedish 
conscripts over a 15 year period and found that the risk of developing schizophrenia was 
positively correlated with the amount of cannabis consumed. They concluded that their 
data was sufficient to indicate cannabis as an independent risk factor for schizophrenia. 
Additionally, several studies have reported abnormal levels of the endocannabinoid 
anandamide in the cerebral spinal fluid of schizophrenic patients (Giuffrida et al., 2004; 
Leweke, Giuffrida, Wurster, Emrich, & Piomelli, 1999). Abnormal receptor density has 
been discovered in schizophrenic patients as well. The dorsolateral prefrontal cortex 
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shows an increase in CB1 receptor binding in non-paranoid schizophrenic patients 
compared to healthy controls, with paranoid schizophrenics showing an increase in 
binding over both groups (Dalton, Long, Weickert, & Zavitsanou, 2011; Dean, Sundram, 
Bradbury, Scarr, & Copolov, 2001). Although not entirely understood, the link between 
schizophrenia and CB1 dysfunction is distinct and could play an important role in 
advancing our knowledge of the disease.       
 
1.4 Research Purpose and Hypothesis 
Given the interplay between CB1, DA, schizophrenia, and emotional perception, 
our overarching goal is to elucidate the neural mechanisms by which functional 
interactions between these systems may lead to aberrant sensory and emotional 
processing deficits. Understanding these mechanisms will undoubtedly be extremely 
beneficial for improving our understanding of highly complex, neuropsychiatric 
disorders. Using a well-established rodent model of associative fear memory, olfactory 
fear conditioning, we have previously shown that activation of CB1 receptors in mPFC 
causes a potentiated fear response to a normally non-salient sensory event, both at the 
single-neuron level and in behaving rats (Laviolette & Grace, 2006a). Although we have 
identified the effects of mPFC CB1 receptor activation at the cortical level, the purpose 
of my research project was to examine how CB1 transmission within the mPFC may 
modulate sub-cortical DA transmission both at the behavioural and neuronal levels of 
analysis. The overarching hypothesis of my thesis is that CB1 receptor transmission 
within the mPFC modulates and controls emotional processing and memory formation 
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through functional interactions with sub-cortical DA signaling, via the mesocorticolimbic 
pathway. I addressed this hypothesis with the following primary AIMS: 
1. Using in vivo neuronal electrophysiology, examine and characterize the effects of 
mPFC CB1 transmission on the spontaneous activity patterns of single DA neurons 
in the VTA 
 
2. Determine how DA transmission is functionally involved in cannabinoid 
modulation of emotional processing and memory formation at the behavioural 
systems level.  
 
3. Examine and characterize how functional interactions between the mPFC and 
VTA mediate the effects of DA and CB1 receptor signaling during emotional 
processing and memory formation. 
 
 
 
2. Materials and Methods 
This research project included 14 behavioural groups with N=5-8 rats per group 
and 102 electrophysiology recordings, with 1-2 cells recorded per rat. The following 
section describes the materials and methods used during the course of the project.  
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2.1 Surgical procedure 
Male Sprague Dawley rats (300-350g) were used for all surgical procedures. They 
were anesthetized using an intraperitoneal (i.p.) injection of a ketamine (80mg/ml) 
xylazine (6mg/ml) mixture and placed in a stereotaxic device. Stainless steel guide 
cannula (22 gauge) were implanted bilaterally into the VTA or the prelimbic subdivision 
of the mPFC using the following stereotaxic coordinates, listed in mm. For the VTA (10˚ 
angle): from bregma, AP -5.0, L ± 2.6; from the dural surface, V -8.0. For the mPFC (15˚ 
angle): from bregma, AP +2.9, L ± 1.9; from the dural surface, V -3.0. Cannulae were 
fixed in place using jeweler’s screws and dental acrylic and all rats were given one week 
of recovery time prior to the beginning of fear conditioning.  
 
2.2 Drug administration 
The following drugs were all used during behavioural or electrophysiological 
experiments: a selective CB1 agonist (WIN 55, 212-2) and antagonist (AM-251), which 
were dissolved in a 10% DMSO/physiological saline solution, a broad-spectrum DA 
antagonist (alpha-flupenthixol), a GABA-A antagonist (bicuculline), and a GABA-B 
antagonist (2-hydroxy-saclofen), which were dissolved in physiological saline (pH 
adjusted to 7.4). During fear conditioning intra-VTA and intra-mPFC bilateral 
microinfusions were performed immediately prior to the conditioning phase, with 0.5µl 
total volume per side being delivered via a 28-gauge microinfusion injector over a period 
of one minute. Microinjectors were left in place for an additional 60 seconds following 
drug infusion to ensure adequate diffusion from the tip. For groups receiving a pre-
treatment of alpha-flupenthixol (α-flu), 0.8mg/kg was delivered via an i.p. injection 2.5 
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hours prior to the conditioning phase. During electrophysiology recordings, 0.5µl of drug 
was infused over a one minute period via a 26-gauge microinjector implanted into the 
region of interest.  
 
 
2.3 Fear conditioning paradigm 
We used an olfactory fear conditioning paradigm to test whether rats could recall 
a learned fear association to an olfactory stimulus that had previously been paired with a 
footshock. By using subthreshold and suprathreshold footshock levels (0.4 and 0.8mA, 
respectively) we were able to test whether specific drug treatments could block or 
potentiate the acquisition of a normal fear memory. In general, a subthreshold footshock 
fails to produce a normal fear response during later testing while a suprathreshold 
footshock has been shown to produce a robust fear memory (Laviolette & Grace, 2006a). 
Two distinct environments were used during experiments. Environment A was a 30” x 
30” Plexiglass box with black spots on a white background and environment B was a 30” 
x 30” Plexiglass box with black and white stripes. The designated “shock” environment 
had a metallic grid shock floor while the designated “test” environment had a smooth 
grey Plexiglass floor. The environments were assigned as “shock” and “test” in a 
counterbalanced manner such that all rats with “shock” environment A were tested in 
environment B and all rats with “shock” environment B were tested in environment A. 
On day one (habituation phase) rats were given sham microinfusions into either the 
mPFC or the VTA and habituated to both “shock” and “test” environments located in a 
sound-attenuated room, spending 30 minutes in each. On day two (conditioning phase) 
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rats were returned to the room, drug infusions were performed, and the animal was placed 
in the previously assigned “shock” environment. Two odors were delivered during the 
course of conditioning, almond and peppermint (Clubhouse brand). One odor was 
presented with a footshock (CS+) and the other was presented in the absence of a 
footshock  (CS-). After one minute in the “shock” environment, the CS- odor was 
presented for 20s. Two minutes later, the CS+ odor was presented for 19s followed by a 
1s footshock delivered through the metallic grid shock floor. This cycle was repeated five 
times after which the rats were returned to their home cages. On day three (testing phase) 
rats were placed in the previously assigned “test” environment. They were given one 
minute to explore the environment before the odor presentation began, during which time 
baseline levels of freezing and exploratory behaviour were recorded. Both CS+ and CS- 
odors were then presented for 5 minutes each and the amount of time the rat spent 
freezing was recorded. Freezing is a well-known behavioural measure of fearfulness and 
was defined as the absence of all movement aside from respiration. We also examined 
exploratory scores in response to CS+ and CS- presentations, as described previously 
(Lauzon et al., 2009; Steven R Laviolette et al., 2005). We assigned a score based on the 
following scale, with each minute of the 5 minute odor presentation being scored 
individually/separately: 0, no locomotion; 1, ambulation across one side of the testing 
chamber; 2, ambulation across two sides; 3, exploration of the full perimeter of the 
testing chamber; and 4, exploration of the center and entire perimeter of the test chamber. 
Thus, each rat received a score for both exploratory behaviour and percentage of time 
spent freezing during the test phase to CS+ and CS- presentations.  
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2.4 Electrophysiology procedure 
We performed single-unit extracellular electrophysiology recordings using 
conventional methods as described in Laviolette et al. (2005). Our two areas of interest 
were the PLC of the mPFC and the VTA, with cell recordings in one region 
corresponding to drug infusion into the other. We distinguished mPFC pyramidal cells 
based on firing frequency, with pyramidal neurons exhibiting a spontaneous firing rate of 
less than 4Hz. For VTA recordings we isolated DA neurons using criteria as described 
previously by Grace and Onn (1989). DA neurons were identified according to well 
established electrophysiological features: (1) a relatively longer action potential width 
(>2.5 ms) calculated automatically by existing software,  a triphasic (+ /-/ +) waveform 
consisting of a notch on the rising phase followed by a delayed afterpotential; (2) a slow, 
irregular or bursting firing pattern, and (3) a spontaneous firing rate of 2–5 Hz or less. In 
contrast, non-DAergic, VTA neurons were characterized based upon previously reported 
criteria: (1) a narrow action potential width (< 1 msec), (2) a biphasic waveform (- / +) 
and (3) relatively fast firing rates (typically ~10-20 Hz) and the absence of bursting 
activity (See Figure 1). For all recording experiments male Sprague Dawley rats (300–
350 g) were anesthetized using urethane (Sigma; 1.4 –1.5 mg/kg, i.p.) and placed in a 
stereotaxic device. Body temperature was monitored with a rectal temperature probe and 
maintained at 37°C. Incisions were made in the scalp to expose the skull, burr holes were 
drilled, and the dura overlying the VTA and mPFC was removed. A 26-gauge 
microinjector (Hamilton, 10ul) was loaded with the appropriate drug treatment and 
slowly lowered into the region of interest (either VTA or mPFC) using the following 
coordinates, listed in mm. For the VTA (no angle): from bregma, AP -5.5, L ± 0.5; from 
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the dural surface, V -6.5-8.0. For the mPFC (20˚ forward angle): from bregma, AP +4.0, 
L ± 0.9; from the dural surface, V -2.5-3.0. Borosilicate glass was used to pull electrodes 
with an impedance, on average, between 6 and 8 MΩ. Electrodes were then filled with 
2% Pontamine Sky Blue and slowly lowered into the VTA or mPFC using the 
coordinates described above. The extracellular signals were amplified using a 
MultiClamp 700B amplifier (Molecular Devices) and recorded through a Digidata 1440A 
acquisition system (Molecular Devices) using pClamp 10 software. Recordings were 
filtered at 1kHz and sampled at 5kHz. Once a cell had been located and proven stable we 
recorded 6-10 minutes of baseline activity before infusing drugs into the region of 
interest. A total volume of 0.5ul of the drug was infused over a period of one minute after 
which time the recording continued for at least 20 minutes, unless the cell became 
unstable during that time frame. For analysis, we compared the frequency of mPFC or 
VTA neuronal cell firing frequency for the 5 minute period before and 5 minute period 
after drug infusion had occurred.  
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Figure Caption 1 
Typical waveforms of both DA and non-DA neurons found within the VTA. Note the 
differences in height, width and after-potential.   
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2.5 Histology 
Following completion of experiments all rats were overdosed on Euthanyl 
(Sodium Pentobarbital, 240mg/kg, i.p.) and perfused using an isotonic saline solution 
followed by 10% formalin. All brains were extracted and placed in the formalin solution 
for at least 24 hours before being placed in a formalin-sucrose solution for at least one 
week before slicing. Brains were sliced using a cryostat at 40µm and mounted onto 
slides. They were stained with cresyl violet and the placements for mPFC and VTA were 
verified using light microscopy. Any rats showing cannula placements outside the 
boundaries defined by Paxinos and Watson (2005) were excluded from data analysis.   
 
2.6 Statistical analyses 
Behavioral and/or electrophysiological data were analyzed with one- or two-way 
ANOVA or Student’s t tests where appropriate. Post hoc analyses were performed with 
Fisher’s LSD tests or Newman–Keuls tests. 
 
3. Results 
 
3.1 The effect of intra-mPFC activation of CB1 receptors on the firing frequency of 
dopaminergic neurons in the VTA 
To study the effect of cortical cannabinoid transmission on subcortical DA 
activity, in vivo extracellular electrophysiology was performed in the VTA during CB1 
receptor activation in the mPFC. Two doses of the CB1 agonist, WIN 55 (low: 
50ng/0.5µl; high: 500ng/0.5µl), were used during experiments, as well as a low dose of 
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the CB1 antagonist, AM-251 (50ng/0.5µl). Once a VTA DA cell was isolated a baseline 
firing frequency was established, after which point the intra-mPFC drug administration 
occurred, followed by a further 30 minutes of recording. We sampled a total of n = 65 
VTA neurons during intra-mPFC infusion of low-dose WIN55 (n=38), high-dose WIN55 
(n=19) and a small control group using AM-251 (n=8). Results from all sampled neurons 
across the three drug treatments are summarized in Figure 2. For rats receiving the low 
dose of intra-mPFC WIN55, 50% of neurons showed increased activity, 32% showed 
decreased activity, and 18% demonstrated no change in activity levels. Interestingly, the 
opposite effect was seen for rats receiving the high dose of intra-mPFC WIN55, where 
26% of neurons showed increased activity, 63% showed decreased activity, and 11% 
demonstrated no change in activity levels. Thus, across both doses of intra-mPFC WIN55 
we observed a biphasic effect where a plurality of cells showed an increase in 
spontaneous neuronal activity patterns after infusion of a low-dose CB1 agonist and a 
plurality of cells showed a decrease in spontaneous neuronal activity patterns after 
infusion of a high-dose CB1 agonist. In Figure 3 we present representative rastergrams 
showing firing frequency patterns during VTA recordings. Figure 3A shows a typical 
increase pattern after mPFC infusion of low-dose WIN55 while Figure 3B shows a 
typical decrease pattern after mPFC infusion of high-dose WIN55. 
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Figure Caption 2 
Summary of the effects of intra-mPFC WIN55 (50 & 500ng/0.5µl) on spontaneous firing 
frequency on sampled neurons recorded in the VTA. A small control group also received 
intra-mPFC WIN55 (50ng/0.5µl) + AM-251 (50ng/0.5µl). 
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Figure Caption 3 
Representative rastergrams showing firing frequency patterns of sampled VTA neurons 
during mPFC drug infusion. For these and subsequent rastergrams bin width is equal to 
1000ms.   
(A) Representative VTA neuronal recording sample demonstrating a typical increase in 
neuronal activity after intra-mPFC WIN55 (50ng/0.5µl). 
(B) Representative VTA neuronal recording sample demonstrating a typical decrease in  
 
neuronal activity after intra-mPFC WIN55 (500ng/0.5µl). 
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Figure 4A displays group data for in vivo recordings performed in the VTA 
during intra-mPFC WIN55 administration for the subpopulations of VTA neurons that 
demonstrated an increase in firing frequency after drug infusion. Two-way ANOVA 
revealed a significant main effect of time (F(1,75) = 30.21, p<0.01). Post hoc analysis 
revealed that VTA neuronal firing frequency was significantly increased relative to 
baseline after infusion of the low-dose CB1 agonist (p<0.01), but not after infusion of the 
high-dose CB1 agonist (p>0.05). Thus, it appears that the low dose of WIN55 was able to 
significantly increase firing frequency in a plurality of VTA cells after intra-mPFC drug 
infusion. While the high dose of WIN55 did increase firing frequency in a small subset of 
VTA cells the effect was non-significant. 
Subpopulations of VTA cells also showed a decrease in firing frequency after 
mPFC drug infusion of WIN55 (Figure 4B). Two-way ANOVA revealed a significant 
main effect of time (F(1,47) = 122.23, p<0.01). Post hoc analysis revealed that VTA 
neuronal firing frequency was significantly decreased relative to baseline after infusion of 
both doses of CB1 agonist (p’s<0.01). Thus, the high dose of WIN55 was able to 
significantly decrease firing frequency in a large majority of VTA cells after intra-mPFC 
drug infusion while the low dose of WIN55 was also able to significantly decrease firing 
frequency in a smaller subset of VTA cells. A representative microphotograph of a mPFC 
injection site is presented in Figure 5A, while a VTA electrode recording site is presented 
in Figure 5B. A schematic representation of VTA recording sites is shown in Figure 5C 
for cells showing an increase in firing frequency at the low dose and a decrease in firing 
frequency at the high dose.  
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Figure Caption 4 
Effects of intra-mPFC WIN55 on spontaneous neural activity in the VTA. For this figure, 
and subsequent figures, * indicates p<0.05 and ** indicates p<0.01 
(A) Intra-mPFC infusions of WIN55 cause a significant increase in firing frequency of 
recorded VTA DA neurons at the 50ng dose, but not the 500ng dose. 
(B) Both 50ng and 500ng doses of intra-mPFC WIN55 cause a significant decrease in 
firing frequency for recorded VTA DA neurons. 
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Figure Caption 5  
Histology of VTA recording sites. 
(A) Microphotograph of an intra-mPFC injection site. Arrows indicate microinjector tip. 
(B) Microphotograph of an intra-VTA electrode recording site. Arrows indicate electrode 
tip. 
(C) A schematic representation showing VTA recording sites for cells that showed an 
increase in firing frequency at the 50ng WIN55 dose (▲) and cells that showed a 
decrease in firing frequency at the 500ng WIN55 dose (○).  
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To demonstrate pharmacological specificity for the effects of intra-mPFC WIN55, 
a separate control experiment was performed using the lower dose of intra-mPFC WIN55 
mixed with AM-251 (50ng/0.5µl), a highly selective CB1 receptor antagonist. In this 
study, 38% of isolated DA neurons showed a trend towards increased activity while 62% 
showed a trend towards decreased activity. Two-way ANOVA revealed no significant 
differences in firing rate after infusion for either subpopulation of cells (F(1,15) = 0.001, 
p>0.05) (Figure 6A). Thus, intra-mPFC co-infusion of WIN55 + AM-251 was able to 
block the increase in firing frequency observed in a plurality of cells after intra-mPFC 
infusion of the low-dose WIN55 alone. A representative rastergram is shown in Figure 
6B, demonstrating a typical firing pattern after mPFC infusion of low-dose WIN55 + 
AM-251. Thus, the effects of intra-mPFC WIN55 are mediated through a CB1-dependent 
substrate, as the co-administration of a selective CB1 receptor antagonist was able to 
block the excitatory effects on sub-cortical DAergic neuron activity in the majority of 
sampled neurons. 
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Figure Caption 6 
The results of AM-251 control experiments. 
(A) Intra-mPFC infusions of WIN55 (50ng/0.5µl) + AM-251 (50ng/0.5µl) did not cause a 
significant increase or decrease in firing frequency for sampled VTA DA neurons.  
(B) Representative VTA neuronal recording sample demonstrating a typical firing pattern 
 
after intra-mPFC WIN55 + AM-251. 
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3.2 Activation of CB1 receptors in VTA excites intra-mPFC pyramidal neurons. 
As noted previously, the mPFC and VTA show functional interactions in a bi-
directional manner, via mPFC>VTA descending or VTA>mPFC ascending projections 
(Sesack & Carr, 2002). In an effort to further characterize the role of CB1 activity within 
the VTA-mPFC circuit we performed the reciprocal experiments as explained above, 
with in vivo electrophysiology being performed in the mPFC during CB1 receptor 
activation in the VTA. As before, two doses of the CB1 agonist, WIN55 (low: 
50ng/0.5µl; high: 500ng/0.5µl) were used during experiments. We sampled a total of n = 
37 mPFC neurons during intra-VTA infusion of low-dose (n=19) and high-dose (n=18) 
WIN55. Results from all sampled neurons across both drug treatments are summarized in 
Figure 7. For rats receiving the low dose of intra-VTA WIN55, 58% of neurons showed 
increased activity and 42% showed decreased activity. A similar effect was seen for rats 
receiving the high dose of intra-VTA WIN55, where 50% of neurons showed increased 
activity, 28% showed decreased activity, and 22% demonstrated no change in activity 
levels. Thus, across both doses of intra-VTA WIN55 administration CB1 activation was 
able to increase spontaneous neural activity in a plurality of sampled neurons within the 
mPFC. 
Figure 8A displays group data for in vivo recordings performed in the mPFC 
during intra-VTA WIN55 administration for the subpopulations of mPFC neurons that 
demonstrated an increase in firing frequency after drug infusion. Two-way ANOVA 
revealed a significant main effect of time (F(1,43) = 43.34, p<0.01). Post hoc analysis 
revealed that mPFC neuronal firing frequency was significantly increased relative to 
baseline after infusion of both the low-dose and high-dose CB1 agonist (p’s<0.01). It 
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appears that both doses of WIN55 were able to significantly increase spontaneous neural 
activity in a majority of sampled cells within the mPFC.   
Subpopulations of mPFC cells also showed a decrease in firing frequency after 
intra-VTA drug infusion of WIN55 (Figure 8B). Two-way ANOVA revealed a 
significant main effect of time (F(1,31) = 20.62, p<0.01). Post hoc analysis revealed that 
mPFC neuronal firing frequency was significantly decreased relative to baseline after 
intra-VTA infusion of both doses of CB1 agonist (p’s<0.05). Thus, both low and high 
doses of WIN55 were able to significantly decrease firing frequency in a smaller 
subpopulation of sampled cells in mPFC.  
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Figure Caption 7 
(A) A schematic representation showing PFC recording sites during intra-VTA infusion 
of 500ng WIN55. 
(B) Summary of the effects of intra-VTA WIN55 (50 & 500ng/0.5µl) on spontaneous 
firing frequency for sampled neurons recorded in the mPFC.  
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Figure Caption 8 
Effects of intra-VTA WIN55 on spontaneous neural activity in the mPFC. 
(A) Intra-VTA infusions of WIN55 cause a significant increase in firing frequency of 
recorded mPFC neurons at both the 50ng and 500ng dose. 
(B) Both 50ng and 500ng doses of intra-VTA WIN55 cause a significant decrease in 
firing frequency for recorded mPFC neurons. 
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3.3 Potentiation of fear acquisition by a low dose CB1 agonist is blocked by a 
dopamine receptor antagonist 
Using our olfactory fear conditioning paradigm, the effects of cortical 
cannabinoid transmission on fear memory acquisition were tested. Previously, it has been 
shown that the activation of CB1 receptors in the mPFC by a low dose of WIN 55 
(50ng/0.5µl) can potentiate a fear response to a normally subthreshold level of footshock 
(Laviolette & Grace, 2006a). In an attempt to further investigate the underlying 
mechanisms of this phenomenon, a low dose of WIN 55 was infused into the mPFC 
during subthreshold fear conditioning. We then challenged the role of DA transmission in 
this potentiated fear memory response by using a broad-spectrum DA antagonist both 
locally (α-flu, 0.1µg or 1µg/0.5µl) and systemically (α-flu, 0.8mg/kg). For local 
application, a low dose of WIN55 was mixed with either a low or high dose of α-flu 
(0.1µg or 1µg/0.5µl) and infused into the mPFC immediately prior to the conditioning 
phase. For systemic application, α-flu (0.8mg/kg) was administered via an i.p. injection 
approximately 2.5 hours prior to the conditioning phase. Infusion of WIN55 (50ng/0.5µl) 
into the mPFC took place immediately prior to the conditioning phase as usual. 
The results of the olfactory fear conditioning experiments revealed that bilateral 
microinfusions of WIN55 into the mPFC were able to potentiate normal freezing 
behaviour to a subthreshold level of footshock. This fear memory potentiation was 
subsequently blocked by intra-mPFC co-infusion of two doses of α-flu (0.1µg/0.5µl & 
1µg/0.5µl) (Figure 9A).  
For groups receiving intra-mPFC WIN55/ -flu co-administration,  analysis of 
conditioned freezing behaviour with two-way ANOVA revealed a significant interaction 
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between group and treatment (F(3,49) = 8.37, p<0.01) on the amount of time spent freezing 
to CS+ vs. CS- presentations. Post hoc analysis revealed that rats receiving intra-mPFC 
WIN55 demonstrated significant levels of conditioned fear, spending a greater amount of 
time freezing to the CS+ presentation than the CS- (n=6, p<0.01). In contrast, the groups 
receiving intra-mPFC saline (n=7), or WIN55 mixed with the lower (0.1µg, n=6) or 
higher (1µg, n=6) doses of α-flu showed no behavioural memory of fear acquisition, with 
equal amounts of time spent freezing to the CS+ and CS- presentations (p’s > 0.05). 
Similarly, two-way ANOVA conducted on spontaneous exploratory behaviour during 
presentations of CS+ and CS- revealed a significant interaction between group and 
treatment (F(3, 49)  = 4.85, p<0.01). Post hoc analysis showed rats treated with intra-mPFC 
WIN55 displayed significantly lower levels of exploratory behaviour during the CS+ 
presentation relative to the CS- (p<0.01) (Figure 9B). In contrast, there was no significant 
difference in exploratory behaviour during CS+ and CS- presentations for groups 
receiving intra-mPFC saline or WIN55 mixed with either dose of α-flu (p’s>0.05).  
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Figure Caption 9  
Effects of intra-mPFC WIN55 on the expression of subthreshold olfactory fear memory. 
(A) A subthreshold level of footshock (0.4mA) produces no fear response in saline 
treated control animals. However, bilateral intra-mPFC infusions of WIN55 (50ng/0.5µl) 
potentiate normal fear memory acquisition, with rats spending an increased amount of 
time freezing to CS+ presentations. This effect was blocked with local administration of 
both doses (0.1 + 1.0µg/0.5µl) of the DA antagonist, α-flu. 
(B) Similarly, intra-mPFC WIN55 was able to attenuate normal exploratory behaviour to 
CS+ presentations. This effect was blocked with local administration of α-flu.   
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To further investigate the effect of DA inhibition on the potentiation of emotional 
associative learning during intra-mPFC cannabinoid activation, we included an 
experiment wherein rats received a systemic dose of α-flu (0.8mg/kg; i.p.). Similar to our 
results with intra-mPFC administration of α-flu, the results of this olfactory fear 
conditioning experiment revealed that systemic administration of α-flu was able to block 
the potentiated fear response seen during intra-mPFC CB1 activation (Figure 10A). 
Analysis of conditioned freezing behaviour with two-way ANOVA revealed a 
significant interaction between group and treatment (F(1,27) = 4.93, p<0.05) on the amount 
of time spent freezing to CS+ vs CS- presentations. Post hoc analysis revealed that rats 
receiving intra-mPFC WIN55 with systemic saline demonstrated significant levels of 
conditioned fear, spending a greater amount of time freezing to the CS+ presentation than 
the CS- (n=6, p<0.01). In contrast, rats receiving intra-mPFC WIN55 with systemic α-flu 
showed no behavioural memory of fear acquisition, with equal amounts of time spent 
freezing to the CS+ and CS- presentations (n=8, p>0.05). Two-way ANOVA of 
exploratory behaviour scores during CS+ and CS- presentations revealed a significant 
main effect of treatment (F(1,27) = 8.71, p<0.01). Post hoc analysis showed rats receiving 
intra-mPFC WIN55 with systemic saline displayed significantly lower levels of 
exploratory behaviour during the CS+ presentation relative to the CS- (p<0.05) (Figure 
10B). Rats receiving intra-mPFC WIN55 with systemic α-flu showed no significant 
difference in exploratory behaviour during CS+ and CS- presentations (p>0.05).     
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Figure Caption 10  
Effects of intra-mPFC WIN55 with systemic α-flu on the expression of olfactory fear 
memory. 
(A) Rats receiving bilateral intra-mPFC infusions of WIN55 (50ng/0.5µl) with saline pre-
treatment showed a potentiation of normal fear memory acquisition, spending an 
increased amount of time freezing to CS+ presentations. This effect was blocked in rats 
receiving bilateral intra-mPFC infusions of WIN55 with α-flu pre-treatment. 
(B) Similarly, intra-mPFC WIN55 was able to attenuate normal exploratory behaviour to 
CS+ presentations. This effect was blocked with systemic administration of α-flu.   
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 To rule out the possibility of altered nociceptive processing mediated by α-flu 
administration we performed a separate group of control experiments to measure 
footshock sensitivity in saline vs. α-flu treated rats. Animals received a systemic injection 
of either saline or α-flu (0.8mg/kg) 2.5 hours prior to the control experiment. Testing took 
place 2.5 hours later when they were placed in a clear Plexiglass environment with a grid 
shock floor. We administered a subthreshold level of footshock once every 60 seconds 
for five minutes and measured sensitivity to footshock over three separate variables: 
mean exploratory score for each minute following footshock, number of jumps in 
response to footshock, and amount of defecation (in pieces) during footshock session. All 
of these behavioural indices of footshock sensitivity are among those reported as reliable 
indicators of fear to the presentation of a footshock stimulus (Antoniadis & McDonald, 
1999). Comparing saline versus α-flu treated rats revealed no significant differences in 
the number of jumps in response to footshock (t(12) = 0.00, p>0.05) (Figure 11A). 
Similarly, there were no significant differences in the amount of defecation during the 
footshock session (t(12) = 0.59, p>0.05) (Figure 11B). We did observe a significant 
difference in the exploratory behaviour scores between saline and α-flu treated rats, with 
saline treated animals having significantly higher exploratory scores (t(6.9) = 4.27, p<0.01) 
(Figure 11C). This observation is to be expected as α-flu is a known cataleptic and would 
therefore impair motor behaviour as compared to the saline treated group. However, as 
testing during our previous experiment took place 24 hours after α-flu administration, the 
rats were all tested in a drug-free state and were thus capable of normal motor movement. 
As the jumping and defecation scores from our sensitivity control experiment indicate, 
the α-flu treated rats were still experiencing normal sensitivity patterns associated with 
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the subthreshold footshock. We can therefore conclude that systemic α-flu administration 
does not cause significant impairments in nociceptive processing to footshock 
presentation.  
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Figure Caption 11 
The results of footshock sensitivity testing. 
(A) Footshock sensitivity testing revealed no significant differences between control and 
α-flu groups for the average number of jumps per trial in response to footshock. 
(B) There were no significant differences between saline and α-flu groups for the average 
amount of defecation per trial. 
(C) There was a significant difference observed in exploratory behaviour between saline 
and α-flu groups. This can be attributed to the known cataleptic properties of α-flu and 
would not be a factory for our main experimental group as testing took place in a drug-
free state. 
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3.4 The effect of high dose CB1 activation on fear acquisition 
To examine the effect of a higher dose of the CB1 agonist, WIN 55, 212-2 
(500ng/0.5ul), on fear memory acquisition, olfactory fear conditioning was performed 
using a suprathreshold footshock level (0.8 mA) which normally produces a robust 
freezing response (Lauzon et al., 2009; Laviolette & Grace, 2006).  As before, all intra-
mPFC infusions were made immediately prior to the behavioural conditioning phase. 
In direct contrast to the potentiating effects of the lower dose of intra-mPFC 
WIN55, the results of the olfactory fear conditioning experiments revealed that bilateral 
microinfusions of high-dose WIN55 (500 ng/0.5 l) into the mPFC blocked normal 
freezing behaviour to a suprathreshold level of footshock (Figure 12A).  
Analysis of conditioned freezing behaviour with two-way ANOVA revealed a 
significant interaction between group and treatment (F(1,31) = 10.42, p<0.01) on the 
amount of time spent freezing to CS+ vs. CS- presentations. Post hoc analysis revealed 
that rats receiving intra-mPFC saline demonstrated significant levels of conditioned fear, 
spending a greater amount of time freezing to the CS+ presentation than the CS- (n=8, 
p<0.01). In contrast, rats receiving intra-mPFC WIN55 (500ng) showed no behavioural 
memory of fear acquisition, with equal amounts of time spent freezing to the CS+ and 
CS- presentations (n=8, p>0.05). Two-way ANOVA of exploratory behaviour scores 
during CS+ and CS- presentations revealed a significant main effect of group (F(1,31) = 
12.40, p<0.01). Post hoc analysis showed rats receiving intra-mPFC saline displayed 
significantly lower levels of exploratory behaviour during the CS+ presentation relative 
to the CS- (p<0.01) (Figure 12B). Rats receiving intra-mPFC WIN55 showed no 
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significant difference in exploratory behaviour during CS+ and CS- presentations 
(p>0.05).  
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Figure Caption 12 
Effects of intra-mPFC WIN55 on the expression of suprathreshold olfactory fear 
memory. 
(A) A suprathreshold level of footshock (0.8mA) produces a robust fear response in 
saline treated control animals. However, bilateral intra-mPFC infusions of WIN55 
(500ng/0.5µl) block normal fear memory acquisition, with rats spending an equal amount 
of time freezing to CS+ and CS- presentations.  
(B) Similarly, saline treated animals showed significantly decreased exploratory 
behaviour to CS+ presentations. This effect was blocked with intra-mPFC WIN55 
(500ng/0.5µl). 
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 3.5 The role of GABA receptors in VTA on dopamine signalling and fear 
acquisition 
Based on the previous electrophysiological and behavioural experiments, I 
hypothesized that the higher dose of WIN55 (500ng) in the mPFC was causing a decrease 
in DA release from the VTA, and hence decreasing overall activity of sub-cortical DA 
transmission within the mesolimbic pathway.  However, while thus far my results have 
determined that higher doses of intra-mPFC WIN55 lead to spontaneous decreases in 
VTA DA neuron activity, the precise mechanism within the VTA that may be causing 
this effect was not known. Given the functional and anatomical complexity of the VTA, 
as well as the role of mPFC inputs to different neuronal elements within the VTA, several 
possible mechanisms may be responsible. For example, it is well established that 
GABAergic interneurons in the VTA provide inhibitory control over mesocortical DA 
neurons (Gysling & Wang, 1983; Johnson & North, 1992; Margolis, Toy, Himmels, 
Morales, & Fields, 2012). Thus, one possibility is that descending mPFC inputs to the 
VTA may modulate VTA DA neuron activity indirectly, via actions on GABAergic 
receptor populations, either associated with non-DA, presumptive VTA GABA neurons, 
or directly upon VTA DA neurons. Considerable evidence demonstrates preferential 
localization of GABA-A receptors on non-DA, presumptive GABAergic VTA neurons, 
whereas GABA-B type GABA receptors are functionally localized to the cell bodies of 
the VTA DA neurons. Given the two distinct populations of GABA receptors in the 
VTA, we were interested in elucidating the possible role of GABA-A and/or GABA-B in 
the activity of sub-cortical DA transmission during cortical cannabinoid activation. Thus, 
we challenged the fear-memory blocking effects of the higher dose of intra-mPFC 
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WIN55 with both a GABA-A receptor antagonist (bicuculline; 5-50 ng/0.5 l) and a 
GABA-B receptor antagonist (hydroxy-saclofen; 10-100 ng/0.5 l) in rats that had 
received quadruple, bilateral cannulae implantations into the VTA and mPFC (see 
methods). Figure 13A shows a representative microphotograph of bilateral intra-VTA 
cannulation placement. Figure 13B shows a schematic representation of bilateral intra-
VTA injector tip placements for three representative experimental groups.   
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Figure Caption 13 
Histology for intra-VTA cannulae placements. 
(A) Microphotograph of representative bilateral intra-VTA cannula placement. 
(B) Schematic representation of intra-VTA injector placements for three experimental 
groups. ○ = intra-mPFC WIN55 (500ng/0.5µl) + intra-VTA bicuculline (50ng/0.5µl).  
● = intra-mPFC WIN55 (500ng/0.5µl) + intra-VTA hydroxy-saclofen (100ng/0.5µl).   
□ = saline control group.   
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3.6 GABA-A receptor blockade in the VTA fails to rescue the block of fear memory 
acquisition induced by intra-mPFC CB1 receptor activation   
We first explored the potential role of intra-VTA GABA-A receptors with the 
selective GABA-A receptor antagonist, bicuculline. We hypothesized that if higher doses 
of intra-mPFC WIN55 inhibited VTA DA neuron activity through a GABA-A receptor-
dependent substrate, blockade of VTA GABA-A receptors would rescue the block of 
associative fear memory acquisition induced by CB1 receptor activation.  Accordingly, 
we performed suprathreshold olfactory fear conditioning using bilateral intra-VTA 
microinfusions of the GABA-A antagonist bicuculline (5ng & 50ng/0.5ul) or saline 
immediately prior to intra-mPFC WIN55 (500 ng/0.5 l) administration. The results of 
the olfactory fear conditioning experiments revealed that neither dose of the GABA-A 
antagonist was capable of rescuing the CB1-mediated block of fear memory acquisition 
(Figure 14A). Rather, behavioural freezing responses were non-associatively increased to 
both CS- and CS+ olfactory cue presentations. 
 Analysis of conditioned freezing behaviour with two-way ANOVA revealed a 
significant interaction between group and treatment (F(3,61) = 3.05, p<0.05) on the amount 
of time spent freezing to CS+ vs. CS- presentations. Post hoc analysis revealed that rats 
receiving intra-mPFC/intra-VTA saline demonstrated significant levels of conditioned 
fear, spending a greater amount of time freezing to the CS+ presentation relative to the 
CS- (n=8, p<0.01). In contrast, rats receiving intra-mPFC WIN55 with intra-VTA saline 
(n=8), 5ng bicuculline (n=8) or 50ng bicuculline (n=7) showed no behavioural memory 
of fear acquisition, with equal amounts of time spent freezing to the CS+ and CS- 
presentations (p’s>0.05). Two-way ANOVA of exploratory behaviour scores during CS+ 
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and CS- presentations revealed a significant main effect of treatment (F(3,61) = 6.99, 
p<0.01). Post hoc analysis showed rats receiving intra-mPFC/intra-VTA saline displayed 
significantly lower levels of exploratory behaviour during the CS+ presentation relative 
to the CS- (p<0.01) (Figure 14B). Rats receiving intra-mPFC WIN55 with intra-VTA 
saline, 5ng bicuculline or 50ng bicuculline showed no significant difference in 
exploratory behaviour during CS+ and CS- presentations (p>0.05).    
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Figure Caption 14 
Effects of intra-mPFC WIN55 (500ng/0.5µl) with GABA-A and GABA-B receptor 
antagonists on the expression of suprathreshold olfactory fear memory. 
(A) A suprathreshold level of footshock (0.8mA) produces a robust fear response in 
saline treated control animals. However, bilateral intra-mPFC infusions of WIN55 
(500ng/0.5µl) block normal fear memory acquisition, with rats spending an equal amount 
of time freezing to CS+ and CS- presentations. Normal fear acquisition was not rescued 
with intra-VTA administration of the GABA-A receptor antagonist, bicuculline. 
However,  intra-VTA administration of a high-dose of the GABA-B antagonist, hydroxy-
saclofen, was able to rescue the block of fear memory acquisition. A low dose of intra-
VTA hydroxy-saclofen was ineffective.   
(B) Similarly, saline treated animals showed significantly decreased exploratory 
behaviour to CS+ presentations. This effect was blocked with intra-mPFC WIN55 
(500ng/0.5µl), intra-VTA bicuculline and low-dose intra-VTA hydroxy-saclofen. A high 
dose of intra-VTA hydroxy-saclofen was able to restore normal fear behaviour to a 
suprathreshold footshock.  
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3.7 GABA-B receptor blockade in the VTA rescues the block of fear memory 
acquisition induced by intra-mPFC CB1 receptor activation   
Following our observation that bicuculline failed to rescue the block of normal 
fear acquisition, we repeated the above experiments using the GABA-B antagonist 
(hydroxy-saclofen) in the VTA. Based on previous literature (Margolis et al., 2012),  I 
hypothesized that the location of GABA-B receptors directly on VTA DA neurons could 
provide a more specific mechanism to modulate DAergic output than our previous 
experiments with the GABA-A receptor antagonist.  Specifically, blocking GABA-B 
receptors located directly on VTA DA neurons would theoretically prevent the effects of 
feed-forward inhibition from GABAergic VTA neurons, thereby reversing the effects on 
VTA DA neuron inhibition induced by intra-mPFC CB1 receptor activation.  
Accordingly, we performed supra-threshold olfactory fear conditioning using bilateral 
intra-VTA microinfusions of the GABA-B antagonist hydroxy-saclofen (10ng & 
100ng/0.5ul) during intra-mPFC WIN55 activation. The results of the olfactory fear 
conditioning experiments revealed that hydroxy-saclofen dose-dependently rescued the 
block of fear memory acquisition. Rats receiving the higher dose of intra-VTA hydroxy-
saclofen (100ng/0.5ul) demonstrated normal associative fear behaviour to a 
suprathreshold footshock and rats receiving the low dose (10ng/0.5ul) demonstrated no 
rescue of associative fear memory behaviour (Figure 14A). 
Analysis of conditioned freezing behaviour with two-way ANOVA revealed a 
significant interaction between group and treatment (F(3,55) = 4.12, p<0.05) on the amount 
of time spent freezing to CS+ vs. CS- presentations. Post hoc analysis revealed that rats 
receiving intra-mPFC WIN55 with high-dose intra-VTA hydroxy-saclofen demonstrated 
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significant levels of conditioned fear, spending a greater amount of time freezing to the 
CS+ presentation relative to the CS- (n=6, p<0.01). In contrast, rats receiving intra-mPFC 
WIN55 with low-dose intra-VTA hydroxy-saclofen showed no behaviour memory of fear 
acquisition, with equal amounts of time spent freezing to the CS+ and CS- presentation 
(n=6, p>0.05). Two-way ANOVA of exploratory behaviour scores during CS+ and CS- 
presentations revealed no significant differences in either group (F(3,55) = 2.68, p>0.05), 
however further analysis revealed a non-significant trend toward decreased exploratory 
behaviour in the high-dose hydroxy-saclofen group as we would expect.  
 
 
4. Discussion 
We have previously reported that CB1 receptor activation in the BLA>mPFC 
pathway is able to potentiate a fear response to a normally non-fearful stimulus during 
associative olfactory fear conditioning (Laviolette & Grace, 2006; Tan et al., 2011). 
While it was evident that cortical cannabinoid transmission was able to alter the 
significance of incoming emotional information, the underlying mechanism(s) for this 
effect was unclear. Based upon the well-established functional relationships between 
cortical cannabinoid transmission and sub-cortical DA signaling, I hypothesized that the 
ability of intra-mPFC cannabinoid transmission to modulate the emotional salience of 
associative conditioning stimuli may depend upon interactions between CB1 receptor 
transmission in the mPFC with sub-cortical DA transmission in the mesolimbic system. 
By using an integrative combination of in-vivo neuronal electrophysiology combined 
with behavioural pharmacology, we were able to examine the effect of mPFC CB1 
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activation on single DA cells in the VTA, and how cortical CB1 transmission modulates 
DA-mediated behavioural conditioning effects at the systems level of analysis. It was 
hypothesized that cannabinoid transmission in the mPFC would cause an increase in DA 
cell activity in the VTA, and that this increased mesolimbic DA activity may serve as a 
mechanism for the behavioural fear-potentiating effects observed during olfactory fear 
conditioning. Furthermore, I directly examined the role of DA transmission in CB1 
mediated behaviours by applying both local or systemic DA antagonists prior to mPFC 
CB1 activation during fear conditioning experiments. My results demonstrated that both 
systemic and direct intra-mPFC blockade of DA transmission were capable of blocking 
the fear-potentiating effects of cortical CB1 receptor activation, demonstrating a 
functional role for of DA transmission in our observed behavioural effects. In my final 
series of experiments, I examined the direct pharmacological mechanisms within the 
VTA that may be responsible for CB1-mediated mPFC modulation of sub-cortical DA 
effects. My results indicated that the ability of higher doses of mPFC CB1 activation to 
blunt DA activity and block fear memory formation depends upon transmission through a 
GABA-B receptor substrate. In summary, the present findings suggest that cortical 
cannabinoid transmission controls sub-cortical DA signaling through a bi-phasic 
mechanism: while lower doses strongly increase midbrain DA neuron activity and cause 
a corresponding potentiation in normally sub-threshold fear-related stimulus memory 
formation, relatively higher doses of an intra-mPFC CB1 agonist cause blunting of 
spontaneous DA neuron activity, concomitant with a block in fear memory acquisition. 
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4.1 Cannabinoid transmission in the medial prefrontal cortex bi-phasically 
modulates sub-cortical dopamine activity: electrophysiological studies 
 Using extracellular in vivo electrophysiology, an interesting biphasic relationship 
was discovered following intra-mPFC CB1 receptor activation. Specifically, during low-
dose intra-mPFC CB1 activation a plurality of intra-VTA DA neurons demonstrated an 
increase in spontaneous firing frequency relative to baseline activity. Meanwhile, a high 
dose of the same intra-mPFC CB1 agonist caused a plurality of intra-VTA DA neurons to 
significantly decrease firing frequency compared to baseline. This biphasic effect is not 
uncommon during CB1 activation and, in fact, many cannabinoid studies have been 
published showing similar results (Katsidoni, Kastellakis & Panagis, 2013; Lepore et al., 
1995; Margulies & Hammer, 1991; Tzavara, Wade, & Nomikos, 2003). Although much 
of the existing evidence varies in terms of the paradigm and the variables being 
measured, it appears that different doses of CB1 agonists can cause varying and 
contrasting results. For example, Lepore et al. (1995) used a conditioned place preference 
(CPP) procedure to evaluate the rewarding properties of systemic application of THC. 
They found that applying low doses of THC (1.0mg/kg) caused a CPP equivalent to using 
10mg/kg of cocaine. In contrast, higher doses of THC (2.0 and 4.0 mg/kg) produced a 
conditioned place aversion. A similar study by Valjent & Maldonado (2000) showed 
comparable results, with a high dose of THC (5.0mg/kg) producing a robust place 
aversion and a lower dose (1.0mg/kg) showing a place preference. However, CPP is not 
the only behavioural paradigm to show a biphasic effect after cannabinoid activation. 
Recently, Katsidoni et al. (2013) reported similar bi-phasic dosing effects when using 
open-field test and intra-cranial self-stimulation (ICSS) during systemic CB1 receptor 
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agonist application. Both behavioural tests revealed a differing role for low-dose vs. high-
dose THC. Thus, during open-field tests a dose of 0.1 mg/kg caused hyperactivity, with 
rats showing increased ambulatory behaviour compared to saline treated animals, while a 
higher dose of 1 mg/kg caused hypoactivity and decreased ambulatory behaviour 
compared to saline treated animals. Meanwhile, during ICSS, a low dose of 0.1 mg/kg 
caused ICSS thresholds to decrease thereby increasing the rewarding effects of 
stimulation. This phenomenon was reversed when using a high dose of 1 mg/kg which 
increased ICSS thresholds and decreased the rewarding effects of stimulation.  
Biphasic effects of cannabinoid modulation are not limited to behavioural studies, 
as differing doses of CB1 agonists have also been shown to have opposing effects at the 
cellular level. For example, in male Sprague Dawley rats, low doses of 0.2 mg/kg THC 
administered intravenously (i.v.) can cause an increase in cerebral metabolism in cortical 
and limbic structures (Margulies & Hammer, 1991). However, at an increased dose of 2 
mg/kg (i.v.) cerebral metabolism was actually reduced in the same cortical and limbic 
structures. Similarly, Tzavara et al. (2003) examined the effect of low and high doses of a 
CB1 agonist on acetylcholine release in the hippocampus. They discovered that low 
doses of systemic WIN55 (0.5 mg/kg, i.p.) were able to cause a short-term stimulation of 
acetylcholine release in the hippocampus while higher doses (5.0 mg/kg, i.p.) caused 
prolonged inhibition of release.  
While it is evident that biphasic effects are seen during cannabinoid modulation, 
the reasons behind this phenomenon are less clear. However, given the well-established 
role that GABAergic interneurons play in providing inhibitory control over VTA DA cell 
populations, we explored the possibility that our observed biphasic effects were mediated 
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by either GABA-A and/or GABA-B receptors in the VTA by performing behavioural 
olfactory fear conditioning, to be discussed presently.   
  
Interestingly, despite the clear biphasic neuronal activity patterns observed during 
intra-VTA recordings, there was no biphasic effect observed for the reverse paradigm of 
intra-mPFC recordings following intra-VTA infusion of WIN55. At both the 50ng and 
500ng doses of intra-VTA WIN55, the plurality of recorded cells in mPFC showed an 
increase in firing frequency. This could be due to the lower density of CB1 receptors in 
VTA, as studies have shown that CB1 levels are much lower in this area as compared to 
other brain regions like the PFC (Herkenham et al., 1991). Considering the lower levels 
of CB1 receptors in VTA it’s possible that the change in dosage was inconsequential. As 
most CB1 receptors in VTA are located on GABAergic interneurons (Lupica et al., 2004; 
Szabo, Siemes, & Wallmichrath, 2002), perhaps the 50ng dose of WIN55 was fully 
saturating intra-VTA CB1 receptors already, which would make the increased dose of 
500ng less likely to produce any further observable effects on neuronal firing rates. By 
acting on presynaptic GABA neurons, both doses of the CB1 agonist were likely 
disinhibiting the primary DA cells which, as discussed previously, can cause an increase 
in PFC pyramidal neuron activity, an effect we observed during electrophysiology 
recordings. Previous research has demonstrated that VTA>mPFC DA transmission 
causes excitatory effects on mPFC neuronal activity (Tseng et al., 2006), suggesting that 
our observed unitary response to intra-VTA CB1 activation may reflect a common action 
of DA on mPFC neuronal activity dynamics. The mPFC does not contain any DA 
neurons, but only receives efferent DA terminals from the VTA. Nevertheless, certainly, 
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the VTA and mPFC share important reciprocal connections in the context of DA 
transmission as the present behavioural results (discussed below) demonstrated that 
blocking DA transmission in the mPFC along with intra-mPFC CB1 receptor activation, 
was capable of blocking intra-mPFC CB1-mediated potentiation of sub-threshold fear 
memory acquisition, presumably via recurrent DA projections back to the mPFC. 
 
4.2 Cannabinoid signaling in the medial prefrontal cortex bi-phasically controls 
emotional fear memory processing through dopamine-dependent mechanisms: 
overview of behavioural results 
During olfactory fear conditioning in awake, behaving animals, we observed that 
a low dose of WIN55 in mPFC was able to potentiate a fear response to a subthreshold 
footshock. Furthermore, it was discovered that this potentiation effect could be blocked 
with either systemic or local administration of a broad-spectrum DA receptor antagonist. 
This finding implies that low-dose cortical cannabinoid transmission is able to increase 
the salience of an emotional stimulus and that this effect is DA-dependent. These findings 
are consistent with previous studies that have shown that intra-mPFC activation of CB1 
receptors (using the same dose of WIN55) is capable of potentiating the behavioural 
effects of normally sub-threshold fear conditioning stimuli (Laviolette & Grace, 2006a). 
Furthermore, systemic administration of WIN55 has been demonstrated to potently 
increase the associative neuronal response to olfactory stimuli paired with footshock, 
when recorded under anesthesia (Laviolette & Grace, 2006a). In the present studies, 
when intra-mPFC DA receptors were blocked during fear conditioning, the potentiation 
effect was no longer observed, implying that the crucial DAergic input responsible for the 
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effect is coming from direct VTA projections, consistent with anatomical evidence 
demonstrating that mPFC>VTA projections, preferentially target VTA DA neurons that 
send recurrent projections back to the mPFC (Sesack & Carr, 2002).      
 
In contrast, when using a high dose of intra-mPFC WIN55 (500ng) during 
olfactory fear conditioning, we were able to block normal fear acquisition to a 
suprathreshold footshock that would normally cause a robust associative fear response in 
control rats. This finding mirrored the results of our electrophysiology recordings where 
we observed a biphasic effect on VTA neuronal activity patterns during low-dose vs. 
high-dose CB1 activation. Furthermore, an intra-VTA GABA-B receptor antagonist, but 
not a GABA-A receptor antagonist, was able to rescue the CB1-mediated block of fear 
acquisition. As discussed above, we hypothesized that the effects observed during both 
electrophysiological recordings and olfactory fear conditioning were due to the activity of 
GABA-A and/or GABA-B receptors directly or indirectly controlling modulation of VTA 
DA neurons. Indeed, existing literature provides an increasing amount of support for this 
theory. For example, GABA-B receptor activation localized on VTA DA neurons can 
control the rewarding properties of various drugs of abuse (Leite-morris, Fukudome, 
Shoeb, & Kaplan, 2004; Wirtshafter & Sheppard, 2001). Furthermore, neuronal recording 
studies in the VTA have demonstrated that activation of GABA-B receptors can directly 
hyperpolarize DA neurons or block glutamate-mediated excitation of the VTA DA 
neurons (Lacey, 1993; Seutin, Johnson, & North, 1994; Wu, Shen, & Johnson, 1999).  
Finally, intra-VTA GABA-B receptor activation leads to decreased somatodendendritic 
release of DA within the mesolimbic pathway (Klitenick, DeWitte, & Kalivas, 1992; 
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Westerink, Kwint, & DeVries, 1996).  In contrast, GABA-A receptor modulation in the 
VTA is linked to the activation of non-DA reward pathways via descending outputs to the 
brainstem (Laviolette & van der Kooy, 2001; Laviolette, Gallegos, Henriksen, & van der 
Kooy, 2004; Laviolette & van der Kooy, 2004). Indeed, blockade of intra-VTA GABA-A 
receptors potently activates a DA-independent reward signal, directly in the VTA 
(Laviolette & van der Kooy, 2001; Laviolette & van der Kooy, 2004). Furthermore, the 
majority of functional GABA-A receptors within the VTA are anatomically localized to 
the non-DA, GABAergic neurons (Churchill, Dilts, & Kalivas, 1992; Klitenick et al., 
1992), where they can indirectly control the activity and output of VTA DA neurons via 
indirect, feedforward inhibitory mechanisms (Grace & Bunney, 1979; Kalivas, 1993; 
Kalivas, Duffy & Eberhardt, 1990).   
In terms of how a higher dose of intra-mPFC WIN55 may be inhibiting VTA DA 
release and spontaneous VTA DA neuron activity, it is possible that while a lower dose 
of WIN55 may preferentially activate descending mPFC > VTA projections that directly 
excite VTA DA neurons (which then activate VTA DA neurons sending recurrent DA 
projections back to the mPFC), a higher dose of intra-mPFC WIN55 may also recruit 
descending mPFC projections that modulate the non-DA, VTA neuronal populations, via 
GABAergic receptor populations. GABA-A receptors in the VTA, given their 
preferential localization to the non-DA, GABAergic neurons, most likely receive GABA 
input from extrinsic, GABAergic terminals feeding into the VTA, such as from the NAc, 
which sends a substantial GABAergic projection to the VTA (Kalivas, Churchill, & 
Klitenick, 1993; Lupica et al., 2004; Walaas & Fonnum, 1980). Excitatory descending 
inputs from the mPFC could theoretically activate these GABAergic neurons, thereby 
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activating feedforward GABA inhibition onto VTA DA neurons, shutting down their 
activity. In contrast, GABA-B receptors would most likely receive GABA input 
downstream from the GABA-A receptors, directly from the GABAergic interneurons 
within the VTA, given their 1) preferential localization on the VTA DA neurons and 2) 
their potent ability to modulate DA-dependent behaviours, discussed above (see Figure 
15).  In this case, descending mPFC inputs to the VTA DA neurons could indirectly 
inhibit VTA DA neurons by increasing activity. Indeed, our observed rescue of fear-
memory blockade supports this idea, with the administration of an intra-VTA GABA-B 
antagonist likely disinhibiting VTA DA neurons, thereby increasing DA output through 
the mesolimbic circuit and re-establishing the normal acquisition of associative olfactory 
fear memory. 
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Figure Caption 15 
Proposed model of the biphasic effects of cannabinoid-mediated subcortical DA activity 
and the localization of GABA-A and GABA-B receptors in the VTA. At low doses, intra-
mPFC CB1 activation acts preferentially on presynaptic receptors located on GABA 
interneurons. Pyramidal neurons are disinhibited and descending glutamatergic 
projections synapse directly onto VTA DA neurons, leading to a net increase in DA 
transmission (indicated by the solid line from pyramidal PFC neuron to VTA DA 
neuron). At high doses, descending projections that synapse onto intra-VTA GABA 
interneurons are also recruited, providing indirect inhibition of DA transmission 
(indicated by dashed line). This inhibition is rescued with an intra-VTA GABA-B, but 
not GABA-A, antagonist.    
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Figure 15 
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5. Future Directions 
The behavioural and electrophysiological results presented here suggest that 
cannabinoid transmission within the frontal cortex controls a bi-phasic, modulatory role 
over sub-cortical DA transmission through the mesocorticolimbic circuit. Relatively 
lower doses of intra-mPFC CB1 agonists potentiated the emotional significance of fear-
related stimuli and this effect was dependent on mesocortical DA activity. In contrast, my 
results demonstrate that relatively higher doses of intra-mPFC cannabinoid agonists can 
strongly decrease DA neuronal activity within the VTA, likely leading to decreased DA 
signaling within mesocorticolimbic DA terminal fields, such as the NAc and mPFC. This 
cannabinoid mediated blunting of sub-cortical DA activity was rescued by concomitant 
blockade of GABA-B receptor signaling directly within the VTA, further demonstrating a 
functional link between descending mPFC inputs to the VTA DA neurons via a GABA-B 
(but not GABA-A) receptor mediated substrate. 
Although we have proposed a mechanism by which these results could be 
explained, further electrophysiological investigations are necessary to fully characterize 
GABAergic receptor activity in the VTA and how signaling via GABA-B receptors may 
functionally modulate cannabinoid-mediated influences from cortical inputs. For 
example, does pharmacological modulation of VTA GABA-B receptors influence 
recurrent DA projections back to the mPFC and might this circuit modulate how 
cannabinoids influence mPFC cortical neuron activity? Furthermore, given the 
importance of the NAc as the primary terminal field for the outputs of VTA DA neurons, 
it will be important to examine 1) how CB1 activity within the mPFC modulates neuronal 
activity patterns within the NAc itself and 2) how mPFC CB1 signaling may influence 
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NAc neuronal responses to VTA DA inputs. Finally, given that the NAc sends recurrent 
projections back to the VTA DA neurons, inactivation of the NAc during mPFC CB1 
transmission could provide further evidence of its involvement in the inhibitory control of 
VTA GABAergic interneurons in the context of the mPFC-VTA-NAc circuitry. 
 Additionally, while I demonstrated a general role for DA transmission within the 
mPFC as being essential for the fear memory-potentiating effects of mPFC CB1 receptor 
activation, it would be worthwhile to investigate whether specific populations of DA 
receptors in mPFC are responsible for mediating the potentiating effects of low-dose 
intra-mPFC cannabinoid activation. For example, previous studies from our lab have 
shown differing roles for D1 vs. D4 receptors in mPFC during emotional processing and 
fear memory formation (Lauzon et al., 2009) so it’s possible that one of these DA 
receptor subtypes could be preferentially modulating the observed effects of CB1 
activation, directly within the mPFC.  
 
5.1 Implications for neuropsychiatric disorders 
In summary, the results reported in this thesis add to a growing body of evidence 
demonstrating that cannabinoids can functionally modulate sub-cortical DA transmission 
in a bi-phasic manner. There are several important clinical implications to be derived 
from the present basic research findings. First, acute exposure to cannabinoids has been 
reported to induce symptoms that are virtually indistinguishable from those observed in 
patients suffering from paranoid schizophrenia (Green et al., 2003; Wachtel et al., 2002). 
Hyperdopaminergia is a well-established model for schizophrenia and as previously 
discussed, excessive DA release is known to mimic some of the psychotic symptoms 
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present in patients with schizophrenia and/or induce such symptoms in otherwise healthy 
individuals (Angrist et al., 1974). Currently, only DA D2 receptor antagonist drugs are 
effective in relieving the psychosis associated with chronic schizophrenia (Kapur & 
Mamo, 2003), demonstrating the critical role that DA signaling plays in the clinical 
profile of schizophrenia. In addition, as previously discussed, there is evidence for CB1 
receptor abnormalities specifically in the prefrontal cortical regions of schizophrenia 
patients, as demonstrated in post-mortem analyses (Dalton et al., 2011; Dean et al., 
2001). This heightened sensitivity to prefrontal cortical cannabinoid activation could 
theoretically pre-dispose such individuals to hyperdopaminergic activation of the 
mesolimbic system, as suggested in the present electrophysiological studies performed in 
rats, wherein acute activation of intra-mPFC CB1 receptor substrates induced an 
abnormal amplification of fear processing, via a DA-dependent mechanism. 
 Conversely, hypodopaminergia may be associated with other neuropsychiatric 
disorders, such as anhedonia, depression and social withdrawal, all of which are often co-
morbid with schizophrenia-related pathology. Interestingly, a recent study from 
Bloomfield et al. (2013) demonstrated that heavy cannabis users had significantly 
reduced DA synthesis capacity in the striatum, suggesting that long-term exposure to 
cannabis may indeed lead to states of hypodopaminergic function. Such findings are in 
addition to longer term studies, such as the longitudinal study by Andreasson et al. (1987) 
demonstrating that the risk of developing schizophrenia in young adulthood was 
positively correlated with the amount of cannabis consumed during adolescence. While 
the present studies did not look specifically at chronic CB1 receptor activation, my 
results indicated that relatively higher acute doses of intra-mPFC CB1 agonists produced 
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strong inhibition of mesolimbic DA activity, and blunted behavioural processing of 
normally highly salient emotional fear memory acquisition. These effects were rescued 
by concomitant blockade of intra-VTA GABA-B receptor substrates, which may 
conceivably suggest a potential pharmacotherapeutic target for treating neuropsychiatric 
symptoms associated with pathological exposure to cannabis, either acutely or 
chronically. 
 
6. Conclusions 
My results demonstrate, for the first time, that cortical cannabinoid transmission 
can control subcortical DA activation via a biphasic mechanism. This effect was 
observed at both the cellular and behavioural level, with lower doses of intra-mPFC 
cannabinoids strongly increasing midbrain DA neuron activity and potentiating a fear 
response to a normally subthreshold stimulus and higher doses causing a decrease in DA 
neural activity and blocking fear memory acquisition to a suprathreshold stimulus. This 
fear memory blockade appears to depend upon a GABA-B receptor substrate as intra-
VTA GABA-B receptor antagonists were able to rescue the CB1-mediated block of fear 
acquisition.  
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